Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis

A. Pardanani, J. Gotlib, A. W. Roberts, M. Wadleigh, S. Sirhan, J. Kawashima, J. A. Maltzman, L. Shao, V. Gupta, A. Tefferi

Research output: Contribution to journal › Letter › peer-review

13 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis'. Together they form a unique fingerprint.